What is Bolden Therapeutics?
Bolden Therapeutics operates at the intersection of advanced biotechnology and neurology, specializing in the development of first-in-class therapeutics designed to stimulate the formation of new brain cells. By targeting specific signaling pathways, the company aims to mitigate the effects of neurodegenerative diseases and cognitive impairment. Their research portfolio is particularly notable for its focus on exon-skipping antisense oligonucleotides, a sophisticated modality intended to address the underlying mechanisms of Alzheimer's disease, stroke recovery, and treatment-resistant depression. As a leader in the CNS therapeutic space, Bolden Therapeutics is systematically bridging the gap between fundamental neuroscience research and scalable clinical applications, positioning itself as a critical player in the future of brain health innovation.
How much funding has Bolden Therapeutics raised?
Bolden Therapeutics has raised a total of $1.5M across 1 funding round:
Other Financing Round
$1.5M
Other Financing Round (2024): $1.5M with participation from Resolute Venture Partners, Slater Technology Fund, and Lifespan Vision Ventures
Key Investors in Bolden Therapeutics
Resolute Venture Partners
A venture capital firm focused on identifying and scaling high-growth potential companies within the life sciences and technology sectors.
Slater Technology Fund
The Slater Technology Fund is an evergreen not-for-profit seed fund dedicated to supporting new venture development in Rhode Island, serving as a cornerstone for regional technology growth.
Lifespan Vision Ventures
An investment group specializing in the healthcare and biotechnology ecosystem, providing strategic backing to firms focused on transformative medical research.
What's next for Bolden Therapeutics?
With this major enterprise-level funding, Bolden Therapeutics is expected to transition into a more aggressive phase of clinical development and operational scaling. The capital will likely be deployed to advance its lead candidates through rigorous preclinical and early-stage clinical trials, while simultaneously expanding its R&D infrastructure to support the discovery of novel therapeutic targets. As the company matures, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities to facilitate the commercialization of its neuro-regenerative pipeline. Investors will be closely monitoring the firm's ability to translate its innovative signaling pathway research into measurable patient outcomes, a key metric for long-term success in the competitive biotechnology landscape.
See full Bolden Therapeutics company page
